| Literature DB >> 23140835 |
Florencia Cano1, Paul J Lehner.
Abstract
By providing ligands for Cytotoxic T-Lymphocytes (CTL) as well as Natural Killer (NK) cells, the HLA-A/B/C MHC class I molecules (MHC-I) play a central role in both innate and adaptive immunity. In addition to CTL-mediated recognition of MHC-peptide complexes, cell surface expression of MHC-I is closely monitored by NK cells, whose killer-cell immunoglobulin-like receptors encode activatory and inhibitory receptors with specificity for MHC-I. How the cell surface expression of MHC-I is tightly controlled is not well understood. In a functional siRNA ubiquitome screen to identify E3 ligases involved in MHC-I regulation we recently found that MEX-3C, a novel RNA-binding ubiquitin E3 ligase, is responsible for the post-transcriptional, HLA-A allotype-specific regulation of MHC-I. MEX-3C expression is increased upon NK cell activation and modulates the threshold of killing by these cells. We find that MEX-3C binds the 3'-untranslated region of HLA-A2 mRNA, inducing its RING-dependent degradation. The RING domain of MEX-3C is not required for HLA-A2 cell surface downregulation, but regulates the degradation of HLA-A2 mRNA. We have therefore uncovered a novel post-transcriptional pathway for regulation of HLA-A allotypes and provide a direct link between ubiquitination and mRNA decay.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23140835 PMCID: PMC3625108 DOI: 10.1016/j.molimm.2012.10.015
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407
Fig. 1MEX-3C specifically regulates HLA-A in NK cells and modulates NK cell killing. Cell surface expression of MHC-I is closely monitored by NK cells, whose activity is regulated by the balance between positive signals from activating receptors and negative signals from MHC-I recognizing inhibitory receptors. NK Inhibitory receptors can bind MHC-I in trans (between opposing membranes, i.e.: on the target cell), as well as in cis (on the same cell membrane). In naive/resting NK cells, inhibitory receptors constitutively bind MHC-I in cis, causing a tonic suppression that prevents spontaneous cellular activation. NK cell activation increases MEX-3C levels, which results in a decrease in surface expression of HLA-A, freeing the potential inhibitory receptor from cis binding, and therefore decreasing the threshold for NK-mediated killing. In this scenario, if the activated NK cell encounters a “healthy cell”, the MHC-I on the target cell engages with the inhibitory receptor in trans resulting in no NK-mediated killing of the target cell. However, if the target cell has low expression of MHC-I, then the NK inhibitory receptor is not engaged. This relieves NK cell inhibition, causing the killing of the target cell. In the absence of MEX-3C, however, HLA-A levels on the surface of the NK cell remain high and bound in cis to the inhibitory receptor, resulting in a decreased level of NK-mediated killing.